Tuesday, 12 December 2017

Questions (306)

Kate O'Connell


306. Deputy Kate O'Connell asked the Minister for Health his views on whether a quality-adjusted life year, QALY, based health technology assessment is an appropriate mechanism for assessing the cost and clinical effectiveness of an orphan medicinal product; if the HSE has found orphan medicinal products to be cost effective under its current health technology assessment; and if he will make a statement on the matter. [52838/17]

View answer

Written answers (Question to Health)

The HSE has statutory responsibility for decisions on pricing and reimbursement of medicines under the community drug schemes, in accordance with the provisions of the Health (Pricing and Supply of Medical Goods) Act 2013; therefore, the matter has been referred to the HSE for reply to the Deputy.